Aerosolized antibiotics to treat ventilator-associated pneumonia

Current Opinion in Infectious Diseases

Volumn 22, Issue 2, 2009, Pages 154-158

  Charles Edouard, Luyt ^a,b   Combes, Alain ^a,b   Nieszkowska, Ania ^a,b   Jean Louis, Trouillet ^a,b   Chastre, Jean ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Aerosol; Aminoglycosides; Antimicrobial treatment; Nosocomial pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; GENTAMICIN; PLACEBO; POLYMYXIN; POLYMYXIN B; TOBRAMYCIN; VANCOMYCIN;

AEROSOL; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; COST; DRUG USE; GRAM NEGATIVE BACTERIUM; HUMAN; LUNG PARENCHYMA; NEBULIZATION; NEBULIZER; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; SPUTUM; TRACHEOBRONCHITIS; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 63849333572     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328322a006     Document Type: Article

References (39)

1. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23-30.
2. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator- associated pneumonia. Respir Care 2007; 52:866-884.
3. Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008; 29:277-296.
4. Waldrep JC, Berlinski A, Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aerosol Med 2007; 20:310-319.
5. Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5:9-18.
6. Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008; 21:45-60.
7. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008; 5:114-119.
8. American Thoracic Society/Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
9. Valcke YJ, Vogelaers DP, Colardyn FA, et al. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992; 101:1028- 1032.
10. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128:545-552.
11. Boselli E, Breilh D, Djabarouti S, er al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med 2007; 33:1519-1523.
12. Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004; 54:508-514.
13. Goldstein I, Wallet F, Nicolas-Robin A, era/. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002; 166:1375-1381.
14. Goldstein I, Wallet F, Robert J, era/. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002; 165:171 -175.
15. Dhand R, Mercier E. Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv 2007; 4:47-61.
16. Ferrari F, Liu ZH, Lu Q, et al. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 2008; 34:1718-1723.
17. Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4:138-146.
18. Palmer LB, Baram D, Duan T, et al. Ventilator-associated pneumonia and clinical pulmonary infection score: effects of aerosolized antibiotics [abstract], Proc Am Thorac Soc 2006; 3:A525.
19. Zarrilli GM, Monteforte M, Baram D, et al. Systemic versus aerosolized delivery of vancomycin for MRSA: concentrations in lungs and serum [abstract]. Am J Respir Crit Care Med 2008; 177:A286.
20. Le Conte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147:1279-1282.
21. Le Conte P, Potel G, Clementi E, et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse Med 2000; 29:76-78.
22. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998; 26:31-39.
23. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med2008; 36:2008-2013.
24. Niederman MS, Chastre J, Corkery K, et al. Inhaled amikacin reduces IV antibiotic use in intubated mechanically ventilated patients [abstract]. Am J Respir Crit Care Med 2007; 175:A326.
25. Niederman MS, Sanchez M, Corkery K, et al. Amikacin aerosol achieves high tracheal aspirate concentrations in intubated mechanically ventilated patients with Gram negative pneumonia: a pharmacokinetic study [abstract]. Am J Respir Crit Care Med 2007; 175:A326.
26. Luyt CE, Jacob A, Combes A, et al. NKTR-061 (inhaled amikacin) achieves high epithelial lining fluid concentrations in Gram-negative pneumonia in intubated and mechanically ventilated patients [abstract]. Am J Respir Crit Care Med 2007; 175:A328.
27. Chastre J, Sanchez M, Corkery K, et al. NTKR-061 achieves safe serum concentrations after repeat dosing in intubated, mechanically ventilated patients with Gram-negative pneumonia: a pharmacokinetic study [abstract]. Am J Respir Crit Care Med 2007; 1 75:A328.
28. Falagas ME, Agrafiotis M, Athanassa Z, et al. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 2008; 6:447-452.
29. Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754-757.
30. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am J Health Syst Pharm 2005; 62:39-47.
31. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102: 407-412.
32. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328-330.
33. Falagas ME, Siempos II, Bliziotis IA, et al. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a metaanalysis of comparative trials. Crit Care 2006; 10:R123.
34. Ehrmann S, Mercier E, Vecellio L, et al. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med 2008; 34:755-762.
35. Luyt CE, Clavel M, Guntapali K, et al. NKTR-061 (inhaled amikacin) BID achieves high epithelial lining fluid concentrations in pneumonic portions of the lung [abstract]. Am J Respir Crit Care Med 2008; 177: A530.
36. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132:761-765.
37. Levy J, Smith AL, Kenny MA, et al. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983; 148:1069-1076.
38. Feeley TW, Du Moulin GC, Hedley-Whyte J, et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293:471 -475.
39. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-2598.